Bayer pays $600M for stem cell therapy developer

Bayer has acquired BlueRock Therapeutics in a deal valued at $600 million that will give the drugmaker a platform to research and develop new stem cell therapies.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news